Against this background, Wortham et al. have nominated small-molecule inhibitors of the sirtuin family member sirtuin 2 (SIRT2) as an innovative class of potential β cell–regenerative drugs for diabetes (Figure 1). This evidence concerns the gene SIRT2 and diabetes mellitus.